Online inquiry

IVTScrip™ mRNA-Anti-ITGA2, GBR500(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ7427MR)

This product GTTS-WQ7427MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 0 & 5-Methyl-CTP & Pseudo-UTP. It ecodes the monoclonal antibody that targets ITGA2 gene. The antibody can be applied in Multiple sclerosis (MS) research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP & Pseudo-UTP
5' Cap Cap 0
Species Humanized
RefSeq NM_002203.4
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 3673
UniProt ID P17301
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-ITGA2, GBR500(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) (GTTS-WQ7427MR). Click the button above to contact us or submit your feedback about this product.

See other products
CAT Product Name Product Type CDs
GTTS-WQ4423MR IVTScrip™ mRNA-Anti-TNFRSF9, BMS-663513(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA BMS-663513
GTTS-WQ4837MR IVTScrip™ mRNA-Anti-SDC1, BT-062(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA BT-062
GTTS-WQ15469MR IVTScrip™ mRNA-Anti-MAPT, UCB-0107(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA UCB-0107
GTTS-WQ14601MR IVTScrip™ mRNA-Anti-CD38, SAR-650984(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA SAR-650984
GTTS-WQ13091MR IVTScrip™ mRNA-Anti-ACVRL1, PF-03446962(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA PF-03446962
GTTS-WQ4022MR IVTScrip™ mRNA-Anti-IL23A, BI 655066(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA BI 655066
GTTS-WQ7936MR IVTScrip™ mRNA-Anti-ICOS, GSK-3359609(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA GSK-3359609
GTTS-WQ815MR IVTScrip™ mRNA-Anti-LRRC15, ABBV-085(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA ABBV-085
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW